Cytek Biosciences, Inc. Financial Ratios
CTKB / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-19.5%
Profit Margin
-33.0%
Net Income / Revenue
Asset Turnover
0.44
Revenue / Total Assets
Equity Multiplier
1.35
Total Assets / Equity
Composite: -19.5% (reported: -19.5%)
Profitability
Liquidity
Current Ratio
5.04
Quick Ratio
4.42
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.44
Inventory Turnover
2.00
Days Sales Outstanding
113 days
As of FY2025 · SEC 10-K · Updated Jul 2, 2026
Earnings Quality
Accrual Ratio
-12.9%
-6.6pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.